Avinger Inc (AVGR) Stock Price, Quote & News

Company Profile

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 650 241 7900

Website: avinger.com

Address:

400 Chesapeake Drive, Redwood City, United States

BairdOakmont Jan. 30 at 8:28 PM

$AVGR When are they filing for CAD approval?

0 · Reply

reality222 Jan. 30 at 7:47 PM

$AVGR Market consolidating quietly

0 · Reply

Buster67 Jan. 29 at 6:30 PM

$AVGR Buyers showing hesitation

0 · Reply

DSky Jan. 5 at 7:11 PM

$AVGR AVINGER... They ARE and HAVE BEEN the entire time since inception MANIPULATING CROOKS and THIEVES, LYING an MISLEADING Shareholders! - They are STILL in partnership with the Chinese Company "Zylox-Tonbridge" for R&D, and Production for Groundbreaking advances in CAD, as well as the entire PAD Product Line ...but completely SILENT ! - Their website since Oct points to a SHADOW Company in Texas called " Lumivascular" (a few months ago a link would direct you to a crude website, but now it's a looping link back to Avinger) WTF ??? !!! - ANY S.H. left after enduring 99.9% Loses has NO WAY to trade/sell out! - The "Liquidation" was just a RUSE to get rid of unwanted manufacturing equipment, office equipment and facility in California. THIEVES, THIEVES, THIEVES!!! WHERE ARE THE LAWSUITS ??? THEY NEED TO BE JAILED, with Monitary Claw-Back's as Restitution! AVINGER is still a corporation in business after stealing +$450 M from shareholders, with No accountability!

1 · Reply

BairdOakmont Jan. 3 at 2:47 PM

$AVGR Why is this stock still listed? Did they finish liquidation proceedings? What is left to do?

0 · Reply

AkilesMusic13 Dec. 29 at 1:58 PM

$AVGR nobody can sell this I wanna sell how can we sell

0 · Reply

Merlintrader Nov. 22 at 4:57 AM

$AVGR https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

3PintBrain Nov. 18 at 1:14 AM

$AVGR Are these crooks still eating lobster or what's the story?

0 · Reply

The_Gambl3r Oct. 17 at 12:57 PM

$AVGR 👀

1 · Reply

Cretandawg Oct. 16 at 3:35 AM

$AVGR wasnt this delisted? how is there action here showing a 20% pop ? i lost hella money here

0 · Reply

Avinger, Inc. Executes Assignment for the Benefit of Creditors; Announces Receipt of Nasdaq Delisting Notice

Nov 7, 2024, 9:43 PM EST - 1 year ago

Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Avinger Reports Third Quarter 2024 Results

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Avinger to Announce Third Quarter 2024 Results on November 7, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Aug 9, 2024, 12:42 PM EDT - 1 year ago

Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Avinger Reports Second Quarter 2024 Results

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Jul 29, 2024, 8:45 AM EDT - 1 year ago

Avinger to Announce Second Quarter 2024 Results on August 8, 2024

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Avinger Announces Closing of up to $24 Million Public Offering

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Avinger Announces Pricing of up to $24 Million Public Offering

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business

May 16, 2024, 4:05 PM EDT - 1 year ago

Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity

May 15, 2024, 6:15 PM EDT - 1 year ago

Avinger, Inc. (AVGR) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:01 PM EDT - 1 year ago

Avinger Reports First Quarter 2024 Results

May 7, 2024, 8:15 AM EDT - 1 year ago

Avinger to Announce First Quarter 2024 Results on May 15, 2024

Mar 20, 2024, 5:56 PM EDT - 2 years ago

Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Avinger Reports Fourth Quarter and Full Year 2023 Results

Mar 12, 2024, 9:00 AM EDT - 2 years ago

Avinger to Announce Full Year 2023 Results on March 20, 2024

Mar 7, 2024, 2:04 AM EST - 2 years ago

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Mar 6, 2024, 7:30 PM EST - 2 years ago

Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge

Oct 26, 2023, 6:23 PM EDT - 2 years ago

Avinger, Inc. (AVGR) Q3 2023 Earnings Call Transcript

Oct 26, 2023, 4:01 PM EDT - 2 years ago

Avinger Reports Third Quarter 2023 Results

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Avinger to Announce Third Quarter 2023 Results on October 26

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Avinger Raises $5.3 Million via At-The-Market Facility

Sep 18, 2023, 11:30 AM EDT - 2 years ago

Avinger stock rockets off a record low after launch of vascular disease treatment system

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023

Aug 4, 2023, 9:00 AM EDT - 2 years ago

Avinger Announces Conversion of 12% of CRG Term Debt into Equity

Jul 27, 2023, 9:54 PM EDT - 2 years ago

Avinger, Inc. (AVGR) Q2 2023 Earnings Call Transcript

Jul 27, 2023, 4:01 PM EDT - 2 years ago

Avinger Reports Second Quarter 2023 Results

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Avinger to Announce Second Quarter 2023 Results on July 27

Jun 20, 2023, 8:00 AM EDT - 2 years ago

Avinger Announces Presentations by Key Opinion Leaders at LINC 2023

Jun 9, 2023, 8:00 AM EDT - 2 years ago

Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Avinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy System

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Avinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion (CTO) Crossing Device

May 10, 2023, 8:38 PM EDT - 2 years ago

Avinger, Inc. (AVGR) Q1 2023 Earnings Call Transcript

May 10, 2023, 4:01 PM EDT - 2 years ago

Avinger Reports First Quarter 2023 Results

May 2, 2023, 8:00 AM EDT - 3 years ago

Avinger to Announce First Quarter 2023 Results on May 10

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium

Apr 26, 2023, 8:00 AM EDT - 3 years ago

Avinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing System

Mar 15, 2023, 9:15 PM EDT - 3 years ago

Avinger, Inc (AVGR) Q4 2022 Earnings Call Transcript

Mar 15, 2023, 4:01 PM EDT - 3 years ago

Avinger Reports Fourth Quarter 2022 Results

Mar 2, 2023, 8:00 AM EST - 3 years ago

Avinger to Announce Fourth Quarter 2022 Results on March 15

Jan 11, 2023, 8:15 AM EST - 3 years ago

Avinger Announces 510(k) Filing of Pantheris LV

Nov 13, 2022, 12:11 PM EST - 3 years ago

Avinger, Inc (AVGR) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 4:01 PM EST - 3 years ago

Avinger Reports Third Quarter 2022 Results

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Avinger Announces Issuance of Seven New Patents Expanding Coverage for Its Proprietary Image-Guided Atherectomy Devices

BairdOakmont Jan. 30 at 8:28 PM

$AVGR When are they filing for CAD approval?

0 · Reply

reality222 Jan. 30 at 7:47 PM

$AVGR Market consolidating quietly

0 · Reply

Buster67 Jan. 29 at 6:30 PM

$AVGR Buyers showing hesitation

0 · Reply

DSky Jan. 5 at 7:11 PM

1 · Reply

BairdOakmont Jan. 3 at 2:47 PM

$AVGR Why is this stock still listed? Did they finish liquidation proceedings? What is left to do?

0 · Reply

AkilesMusic13 Dec. 29 at 1:58 PM

$AVGR nobody can sell this I wanna sell how can we sell

0 · Reply

Merlintrader Nov. 22 at 4:57 AM

$AVGR https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

3PintBrain Nov. 18 at 1:14 AM

$AVGR Are these crooks still eating lobster or what's the story?

0 · Reply

The_Gambl3r Oct. 17 at 12:57 PM

$AVGR 👀

1 · Reply

Cretandawg Oct. 16 at 3:35 AM

$AVGR wasnt this delisted? how is there action here showing a 20% pop ? i lost hella money here

0 · Reply

Caecias Oct. 14 at 9:06 PM

$AVGR When prison?

1 · Reply

Miok Sep. 22 at 11:18 PM

$AVGR delist yet? June 23, 2025 - 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

0 · Reply

Cretandawg Aug. 31 at 4:08 PM

$AVGR to think I work in the same city as this shitty company who screwed us shareholders. My bags are heavy here

0 · Reply

Jackattack209 Aug. 31 at 3:20 PM

$AVGR eff this company! Scam

0 · Reply

Camelinvesting Aug. 17 at 2:27 PM

$AVGR buying zone ? Agreed ?

1 · Reply

Terminator1 Aug. 12 at 6:57 PM

$AVGR $TNXP really??

2 · Reply

MGeronimo Jul. 27 at 3:37 PM

$AVGR HOPING FOR AROUND 2.2 million in revenue

1 · Reply

MGeronimo Jul. 18 at 3:26 AM

$AVGR https://seekingalpha.com/news/4081775-avinger-gaap-eps-of-3_93-misses-6_48-revenue-of-1_9m-misses-0_62m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news

1 · Reply

The_eye_of_the_tiger Jul. 14 at 8:23 AM

$AVGR Hosting is paid for a year, it doesn't them anything to be online.

1 · Reply

Market Cap	1.57M
Revenue (ttm)	7.65M
Net Income (ttm)	-18.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-239.48%
Debt to Equity Ratio	1.07

Volume	2,592,000
Avg Vol	3,817,300
Day's Range	N/A - N/A
Shares Out	3.31M
Stochastic %K	24%
Beta	1.09
Analysts	Strong Sell
Price Target	$5.00